You are here

Abattis Bioceuticals Corp.

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
ATT
CSE Index: 
Currency: 

Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets, some of which will contain cannabinoid compounds. Abattis develops and is in the process of commercializing natural health products that target ailments and satisfy important market needs. Abattis is conducting ongoing research and development to create plant-based intellectual property and ingredients. Current areas of focus are growth through acquisition and business development and cash flow through commercialization of existing assets. The Company has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. Abattis follows strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

You are here

Abattis Bioceuticals Corp. (ATT)

SEDAR Information

Abattis Bioceuticals Corp.
Date: September 18, 2017
Abattis Bioceuticals Corp.
Date: September 13, 2017
Abattis Bioceuticals Corp.
Date: August 29, 2017
Abattis Bioceuticals Corp.
Date: August 29, 2017
Abattis Bioceuticals Corp.
Date: August 29, 2017
Abattis Bioceuticals Corp.
Date: August 29, 2017
Abattis Bioceuticals Corp.
Date: August 28, 2017
Abattis Bioceuticals Corp.
Date: August 23, 2017
Abattis Bioceuticals Corp.
Date: August 21, 2017

Company Info

Address
224 – 970 Burrard Street
Vancouver, BC V6Z 2R4
Canada
Phone
604-336-0881
Email
news@abattis.com
Website
http://www.abattis.com
Listing date
Thursday, December 23, 2010
Transfer Agent
Computershare Investor Services Inc.
Auditor
DALE MATHESON CARR-HILTON LABONTE LLP

Advertisement

Publicité

Capitalization

Issued & Outstanding: 
162698887
Reserved for Issuance: 
0

Bulletins

03/03/2017

2017-0301 - Reinstatement - Abattis Bioceuticals Corp. (ATT)

March 3, 2017

Effective immediately the shares of Abattis Bioceuticals Corp. will be reinstated for trading.

The Company has rectified the default situation that gave rise to the suspension.

Effective Date: March 3, 2017

Symbol:  ATT

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com